Overview

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Arcus Biosciences, Inc.
Collaborator:
Gilead Sciences
Treatments:
Docetaxel